[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.

[18F]RCCB6 PET/CT detects ccRCC metastases with 94.2% sensitivity, outperforming [18F]FDG PET/CT and conventional imaging in accuracy and specificity.

• Why it matters: Accurate detection of metastases in clear cell renal cell carcinoma (ccRCC) is critical for effective treatment planning, but current imaging methods have limitations in sensitivity and specificity.
• What they did: The study prospectively evaluated 150 patients using [18F]RCCB6 PET/CT, comparing its performance to [18F]FDG PET/CT and conventional imaging across hundreds of lesions, and analyzing correlation with CD70 expression.
• The result: [18F]RCCB6 PET/CT demonstrated superior sensitivity and specificity, significantly influencing clinical management in nearly 60% of patients, and its uptake correlated strongly with CD70 expression, supporting its diagnostic value.